Glaukos (GKOS) said its Phase 4 trial of iDose TR given during cataract surgery met the primary endpoint, showing statistically superior IOP reduction versus cataract surgery alone. Mean diurnal IOP dropped 11.1 mmHg vs 7.4 mmHg at three months. Safety was favorable.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
